NIH Reporter #5R35GM155168-03

Pharmacomicrobiomics: The Frontier of Interindividual Variability in Drug Response

This NIH-funded project at the University of North Carolina at Chapel Hill studies how gut bacteria affect drug response variability, aiming to improve drug safety and efficacy predictions through pharmacomicrobiomics.

Description

The research aims to develop pharmacomicrobiomics, studying drug-microbiota interactions that drive variable drug responses. The focus is on bacterial enzymes like β-glucuronidase (GUS) and their role in drug toxicity and efficacy, utilizing high-throughput primary cell culture platforms. The research includes two programs: one testing the hypothesis that gut microbiota contribute to variability in bacterial reactivation of drug-glucuronide conjugates, and another assessing tissue susceptibility to bacterial drug metabolism. This work aims to integrate bacterial drug metabolism into physiologically based pharmacokinetic models to improve prediction of drug side effects and efficacy.

View original record